Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.54 |
| ▸ | LMNA | P02545 | 5/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.54 |
| ▸ | TUBB | P07437 | 2/20 | 0.54 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.54 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.54 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.54 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.54 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.54 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.54 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.54 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.54 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14097830 | 1.00 | CYP3A4 (0.54) | CYP3A4LMNASMN1; SMN2CYP2C9MAPK1 | |
| Steganacin SCHEMBL66054 | 0.86 | LMNA (0.57) | CYP3A4LMNASMN1; SMN2CYP2C9MAPK1 | |
| Steganacin SCHEMBL14138211 | 0.86 | LMNA (0.57) | CYP3A4LMNASMN1; SMN2CYP2C9MAPK1 | |
| (-)-Steganacin SCHEMBL10065023 | 0.86 | LMNA (0.57) | CYP3A4LMNASMN1; SMN2CYP2C9MAPK1 | |
| SCHEMBL9951919 | 0.81 | GSK3B (0.47) | CYP3A4LMNACYP2C9MAPK1CYP2C19 | |
| Stegane SCHEMBL5014561 | 0.80 | TUBB4A (0.53) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Picrostegane SCHEMBL14097820 | 0.80 | TUBB4A (0.53) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Steganacin SCHEMBL8044045 | 0.77 | CYP3A4 (0.48) | CYP3A4LMNASMN1; SMN2CYP2C9MAPK1 | |
| SCHEMBL19050768 | 0.77 | CYP3A4 (0.53) | CYP3A4LMNASMN1; SMN2CYP2C9MAPK1 | |
| SCHEMBL14363336 | 0.77 | CYP3A4 (0.54) | CYP3A4LMNASMN1; SMN2CYP2C9MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194678-A1 | Process To Obtain Synthetic And Semi-Synthetic Lignan Derivatives, Their Antiparasitic Activities And Corresponding Pharmaceutical Formulations, Including The Therapeutic Method Using Said Lignan For The Treatment Of Parasitosis | FUNDACAO DE AMPARO A PESQUISSA DO ESTADO DE AAO PA (BR) | 2008-08-14 | — | — | US | claimed |
| EP-1907380-A2 | PROCESS TO OBTAIN SYNTHETIC AND SEMI-SYNTHETIC LIGNAN DERIVATIVES, THEIR ANTIPARASITIC ACTIVITIES AND CORRESPONDING PHARMACEUTICAL FORMULATIONS, INCLUDING THE THERAPEUTIC METHOD USING SAID LIGNAN FOR THE TREATMENT OF PARASITOSIS | Fundação de Amparo à Pesquisa do Estado de São Paulo - FAPESP (BR) | 2008-04-09 | — | — | EP | claimed |
| WO-2007009201-A2 | PROCESS TO OBTAIN SYNTHETIC AND SEMI-SYNTHETIC LIGNAN DERIVATIVES, THEIR ANTIPARASITIC ACTIVITIES AND CORRESPONDING PHARMACEUTICAL FORMULATIONS, INCLUDING THE THERAPEUTIC METHOD USING SAID LIGNAN FOR THE TREATMENT OF PARASITOSIS | Fundação De Amparo À Pesquisa Do Estado de São Paulo (BR) | 2007-01-25 | — | — | WO | claimed |
| CN-118063558-A | Polypeptide with anti-pulmonary fibrosis effect and application thereof | 南方科技大学 | 2024-05-24 | — | — | CN | disclosed |
| US-20080194678-A1 | Process To Obtain Synthetic And Semi-Synthetic Lignan Derivatives, Their Antiparasitic Activities And Corresponding Pharmaceutical Formulations, Including The Therapeutic Method Using Said Lignan For The Treatment Of Parasitosis | FUNDACAO DE AMPARO A PESQUISSA DO ESTADO DE AAO PA (BR) | 2008-08-14 | — | — | US | disclosed |
| EP-1907380-A2 | PROCESS TO OBTAIN SYNTHETIC AND SEMI-SYNTHETIC LIGNAN DERIVATIVES, THEIR ANTIPARASITIC ACTIVITIES AND CORRESPONDING PHARMACEUTICAL FORMULATIONS, INCLUDING THE THERAPEUTIC METHOD USING SAID LIGNAN FOR THE TREATMENT OF PARASITOSIS | Fundação de Amparo à Pesquisa do Estado de São Paulo - FAPESP (BR) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007009201-A2 | PROCESS TO OBTAIN SYNTHETIC AND SEMI-SYNTHETIC LIGNAN DERIVATIVES, THEIR ANTIPARASITIC ACTIVITIES AND CORRESPONDING PHARMACEUTICAL FORMULATIONS, INCLUDING THE THERAPEUTIC METHOD USING SAID LIGNAN FOR THE TREATMENT OF PARASITOSIS | Fundação De Amparo À Pesquisa Do Estado de São Paulo (BR) | 2007-01-25 | — | — | WO | disclosed |
| US-4059593-A | Synthesis of steganacin and derivatives thereof | UNIVERSITY OF ROCHESTER (US) | 1977-11-22 | — | — | US | disclosed |
| US-4003916-A | ANTI-LEUKEMIC AGENTS; DIBENZO-CYCLOOCTADIENE LIGNIN LACTONES; SAPONIFICATION | KENDE ANDREW S | 1977-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194678-A1 | Process To Obtain Synthetic And Semi-Synthetic Lignan Derivatives, Their Antiparasitic Activities And Corresponding Pharmaceutical Formulations, Including The Therapeutic Method Using Said Lignan For The Treatment Of Parasitosis | HRH4, NISCH, CCNB3 | CYP3A4 259/4885LMNA 813/4885SMN1; SMN2 3844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.